MetaVia Inc. MetaVia Inc.

MetaVia Inc.

MTVA

Ранг среди акций #33007
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Цена акции
$1.24
Последняя синхронизация: 2026-10-19
Рыночная капитализация
$8.17M
Изменение (1 день)
-1.59%
Изменение (1 год)
-23.93%
Страна
US
Торговля MetaVia Inc. (MTVA)

Категория

Healthcare
История дивидендов MetaVia Inc. (MTVA)
MetaVia Inc. (тикер: MTVA) выплатила в общей сложности 0 дивидендов.
Общая сумма всех дивидендов (с учетом дроблений акций): 0.00
Дивидендная доходность (TTM): 0
Дивидендные выплаты по MetaVia Inc. (MTVA) с 2026 по 2026
Годовые дивидендные выплаты
Год Дивиденды (с учетом дробления акций) Изменить
Недостаточно данных для указанных дат.
Список всех дивидендных выплат
Год Дивиденд Изменить
Недостаточно данных для указанных дат.
Дивиденды аналогичных компаний или конкурентов
Компания Количество дивидендных выплат Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL